Cisplatin or carboplatin in the treatment of non-small cell lung cancer: A comprehensive review

Oncology Reviews

Volumn 1, Issue 3, 2007, Pages 162-169

  Tiseo, Marcello ^a   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Carboplatin; Cisplatin; Non small cell lung cancer

Indexed keywords

EID: 57649086846     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-007-0019-z     Document Type: Review

References (43)

1. Johnson SW, O'Dwyer PJ (2005) Pharmacology of cancer chemotherapy: cisplatin and its analogues. In: De Vita VT Jr, Hellman S, Rosenberg SA, (eds) Cancer: Principles and Practice of Oncology. 7th ed. Lippincott Williams & Wilkins, Philadelphia 344-358
2. Weiss RB (2005) Adverse effects of treatment: miscellaneous toxicities. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds) Cancer. Principles and Practice of Oncology. 7th ed. Lippincott Williams & Wilkins, Philadelphia 2602-2614
3. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422 (Pubitemid 29022420)
4. Lokich J, Anderson N (1998) Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 9:13-21 (Pubitemid 28125759)
5. Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30 (Pubitemid 40310185)
6. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899-909
7. Waters JS, O'Brien MER (2002) The case for the introduction of new chemotherapy agents in the treatment of advanced non-small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br J Cancer 87:481-449
8. Pfister DG, Johnson DH, Azzoli CG et al (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22:330-353 (Pubitemid 41095099)
9. Besse B (2007) Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up of. Ann Oncol 18 [Suppl 2]: ii30-ii31.
10. Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced nonsmall-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218 (Pubitemid 32591438)
11. Scagliotti GV, De Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum based doublets in advanced non small cell lung cancer. J Clin Oncol 20:4285-4291 (Pubitemid 35266288)
12. Berghmans T, Paesmans M, Sculier JP (2001) Cisplatin or carboplatin for the treatment of non-small cell lung cancer: do they have equivalent efficacy? Lung Cancer 34:15-17 (Pubitemid 32824118)
13. Soria JC, Le Chevalier T (2002) Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann Oncol 13:1515-1517 (Pubitemid 35331448)
14. Einhorn LH (2005) Carboplatin versus cisplatin in lung cancer. Lung Cancer 49 [Suppl 3]:S32-S35
15. Hotta K, Matsuo K (2007) Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancer. J Thorac Oncol 2:96 (Pubitemid 47163939)
16. Klastersky J, Sculier J, Lacroix J et al (1990) A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 8:1556-1562 (Pubitemid 20301187)
17. Jelic S, Mitrovic L, Radosavljevic D, et al (2001) Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study. Lung Cancer 34:1-13 (Pubitemid 32824117)
18. Bisset D, Nicolson M, Falk S et al (2001) Randomized phase II study of tirapazamine with either cisplatin or carboplatin in advanced NSCLC. Proc Am Soc Clin Oncol 20:abstract 1381.
19. Rosell R, Gatzemeier U, Betticher DC et al (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539-1549 (Pubitemid 35331451)
20. Schiller JH, Harrington D, Belani CP, et al (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98 (Pubitemid 34438899)
21. Zatloukal P, Petruzelka L, Zemanova M et al (2003) Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in stage IIIB and IV non-small cell lung cancer (NSCLC): a phase III randomized trial. Lung Cancer 41:321-331 (Pubitemid 36970188)
22. Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations vs vinorelbine plus cisplatin for advanced non-small cell lung cancer: The TAX 326 Study Group. J Clin Oncol 21:3016-3024 (Pubitemid 46606280)
23. Mazzanti P, Massacesi C, Rocchi MBL et al (2003) Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced nonsmall-cell lung cancer. Lung Cancer 41:81-89 (Pubitemid 36765487)
24. Paccagnella A, Favaretto A, Oniga F et al (2004) Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non-small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 43:83-91 (Pubitemid 38096297)
25. Ardizzoni a, Boni L, Tiseo M et al (2007) Cisplatin- versus carboplatinbased chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data metaanalysis. J Natl Cancer Inst 99:847-857
26. Hotta K, Matsuo K, Ueoka H et al (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852-3859 (Pubitemid 41079865)
27. Zojwalla NJ, Raftopoulos H, Gralla RJ (2004) Are cisplatin and carboplatin equivalent in the treatment of nonsmall cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2500 patients. Proc Am Soc Clin Oncol 23:abstract 7068.
28. Chan AM, Mao AJ, Wu T, Zhang Y (2005) Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced Non-small Cell Lung Cancer. Proc Am Soc Clin Oncol 24:abstract 7218.
29. Jiang J, Liang X, Zhou X et al (2007) A meta-analysis of randomized controlled trials comparing carboplatinbased to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348-358 (Pubitemid 47285418)
30. Piedbois P, Buyse M (2004) Metaanalyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 22:3839-3841 (Pubitemid 41079861)
31. Clemente S, Barradas P. Alves P et al (2007) What is the standard platinumderivative based-chemotherapy for advanced or metastatic NSCLC: a 10-years trial comparing cisplatin and carboplatin in combination with gemcitabine. J Thorac Oncol 2 [Suppl]:S671
32. Chen YM, Perng RP, Tsai CM, Whang-Peng J (2006) A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. J Thorac Oncol 1:141-145 (Pubitemid 47164001)
33. Rajeswaran A, Trojan A, Burnand B, Giannelli M (2007) Efficacy and side effects of cisplatin- and carboplatinbased doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer Aug 27; [Epub ahead of print].
34. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
35. Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191 (Pubitemid 41095154)
36. Manegold C, von Pawel J, Zatloukal P et al (2001) Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapynaïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25[18 suppl]:LBA7514.
37. Arriagada R, Bergman B, Dunant A et al (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360 (Pubitemid 38101630)
38. Winton T, Livingston R, Johnson D et al (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597 (Pubitemid 41007845)
39. Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol 7:719-727 (Pubitemid 44283661)
40. Pignon JP, Tribodet H, Scagliotti GV et al (2006) Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. Proc Am Soc Clin Oncol 24:abstract 7008.
41. Strauss GM, Herndon JE II, Maddaus MA et al (2006) Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Proc Am Soc Clin Oncol 24:abstract 7007.
42. Azzoli CG, Kris MG, Pfister DG (2007) Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer-an old rivalry renewed. J Natl Cancer Inst 99:828-929
43. Hotta H, Kiura K (2006) Role of platinum-based radio-chemotherapy for locally advanced non-small-cell lung cancer: possible influence of type of platinum on survival data. Ann Oncol 17:1724. (Pubitemid 44680900)